Target Validation Information
Target ID T84621
Target Name Cytochrome P450 11B1, mitochondrial
Target Type
Successful
Drug Potency against Target 1-(4-Cyanobenzyl)-5-(2-methylphenyl)-1H-imidazole Drug Info IC50 = 5.7 nM [530679]
3-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine Drug Info IC50 = 578 nM [529624]
3-(6-Methoxynaphthalen-2-yl)pyridin-4-amine Drug Info IC50 = 1521 nM [529624]
5-[5-Bromo-indan-(1Z)-ylidenemethyl]-1H-imidazole Drug Info IC50 = 23.5 nM [527475]
6-[4-(Pyridin-4-ylmethyl)phenyl]naphthalen-2-ol Drug Info IC50 = 627 nM [531085]
4-(4-(thiophen-2-yl)benzyl)pyridine Drug Info IC50 = 415 nM [531085]
3-Fluoro-4'-(pyridin-4-ylmethyl)biphenyl-4-ol Drug Info IC50 = 850 nM [531085]
4-((3',4'-Difluorobiphenyl-4-yl)methyl)pyridine Drug Info IC50 = 4742 nM [531085]
4-(4-(thiophen-3-yl)benzyl)pyridine Drug Info IC50 = 422 nM [531085]
3-Phenanthren-9-yl-pyridine Drug Info IC50 = 7553 nM [527801]
4'-(Pyridin-4-ylmethyl)biphenyl-4-amine Drug Info IC50 = 522 nM [531085]
2-Methyl-1,2-di-pyridin-3-yl-propane Drug Info IC50 = 2640 nM [533562]
3-[4-Methyl-indan-(1E)-ylidenemethyl]-pyridine Drug Info IC50 = 763 nM [527456]
4-(6-Methoxy-3-methylnaphthalen-2-yl)isoquinoline Drug Info IC50 = 843 nM [529624]
5-Pyridin-3-yl-1,3-dihydro-2H-indol-2-one Drug Info IC50 = 5952 nM [529834]
3-(6-Methoxy-3-methylnaphthalen-2-yl)pyridine Drug Info IC50 = 1047 nM [529624]
3-[5-Ethoxy-indan-(1E)-ylidenemethyl]-pyridine Drug Info IC50 = 2368 nM [527456]
3-Ethoxy-5-(6-methoxynaphthalen-2-yl)pyridine Drug Info IC50 = 373 nM [529624]
4-[(4'-Hydroxybiphenyl-4-yl)methyl]pyridine Drug Info IC50 = 251 nM [531085]
2-Methyl-1,2-di-pyridin-3-yl-propyliodide Drug Info IC50 = 5360 nM [533562]
3-(6-Ethoxy-naphthalen-2-yl)-pyridine Drug Info IC50 = 5419 nM [527801]
1-Benzyl-5-phenyl-1H-imidazole Drug Info IC50 = 4.8 nM [530679]
3-(5-methoxy-1H-inden-2-yl)pyridine Drug Info IC50 = 5684 nM [528109]
1-(3,4-dihydronaphthalen-2-yl)-1H-imidazole Drug Info IC50 = 639 nM [528109]
5-Naphthalen-2-yl-oxazole Drug Info IC50 = 805 nM [527801]
4-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine Drug Info IC50 = 2529 nM [528109]
6-Isoquinolin-4-yl-3,4-dihydroquinolin-2(1H)-one Drug Info IC50 = 33 nM [529834]
3-methoxy-5-(6-methoxynaphthalen-2-yl)pyridine Drug Info IC50 = 238 nM [529624]
METYRAPOL Drug Info IC50 = 7050 nM [533562]
5-[5-Bromo-indan-(1E)-ylidenemethyl]-1H-imidazole Drug Info IC50 = 26.2 nM [527475]
R-fadrozole Drug Info IC50 = 119 nM [530679]
1-(3-Fluorobenzyl)-1H-imidazole Drug Info IC50 = 206 nM [530679]
1-(4-Cyanobenzyl)-5-(3-methylphenyl)-1H-imidazole Drug Info IC50 = 6.2 nM [530679]
Methyl 3-(1-Benzyl-1H-imidazol-5-yl)-propanoate Drug Info IC50 = 326 nM [530679]
BENZYLIMIDAZOLE Drug Info IC50 = 709 nM [530679]
4-((1H-imidazol-1-yl)methyl)benzonitrile Drug Info IC50 = 368 nM [530679]
1-(4-Cyanobenzyl)-5-methyl-1H-imidazole Drug Info IC50 = 141 nM [530679]
1-(4-Chlorobenzyl)-5-phenyl-1H-imidazole Drug Info IC50 = 25 nM [530679]
3-(1-methyl-3,4-dihydronaphthalen-2-yl)-pyridine Drug Info IC50 = 1268 nM [528109]
3-(3-Benzylnaphthalen-2-yl)pyridine Drug Info IC50 = 953 nM [529667]
1-(6-Methoxy-naphthalen-2-yl)-1H-imidazole Drug Info IC50 = 849 nM [527801]
3-(4-ethyl-3,4-dihydronaphthalen-2-yl)pyridine Drug Info IC50 = 1615 nM [528109]
(3-((1H-imidazol-1-yl)methyl)phenyl)methanol Drug Info IC50 = 206 nM [530679]
1-(4-fluorobenzyl)-1H-imidazole Drug Info IC50 = 494 nM [530679]
3-(1-Benzyl-1H-imidazol-5-yl)-1-propanol Drug Info IC50 = 181 nM [530679]
1-(4-Bromobenzyl)-5-phenyl-1H-imidazole Drug Info IC50 = 7 nM [530679]
3-Imidazol-1-yl-quinoline Drug Info IC50 = 6338 nM [527801]
1-(4-Cyanobenzyl)-5-formyl-1H-imidazole Drug Info IC50 = 478 nM [530679]
1-(4-Methoxybenzyl)-5-phenyl-1H-imidazole Drug Info IC50 = 11 nM [530679]
1-(4-Cyanobenzyl)-5-(3-fluorophenyl)-1H-imidazole Drug Info IC50 = 32 nM [530679]
4-[5-Chloro-indan-(1E)-ylidenemethyl]-pyridine Drug Info IC50 = 1515 nM [527456]
(4-((1H-imidazol-1-yl)methyl)phenyl)methanol Drug Info IC50 = 695 nM [530679]
3-[(Z)-2-phenylvinyl]pyridine Drug Info IC50 = 288 nM [528109]
3-[5-Methoxy-indan-(1Z)-ylidenemethyl]-pyridine Drug Info IC50 = 790 nM [527456]
6-Pyridin-3-yl-3,4-dihydro-1H-quinolin-2-one Drug Info IC50 = 6746 nM [529834]
6-Pyridin-3-yl-3,4-dihydronaphthalen-2(1H)-one Drug Info IC50 = 3964 nM [529834]
7-Pyridin-3-yl-2H-1,4-benzothiazin-3(4H)-one Drug Info IC50 = 525 nM [529834]
3-[1-(4-Cyanobenzyl)-1H-imidazol-5-yl]-1-propanol Drug Info IC50 = 48 nM [530679]
1-(3-Chlorobenzyl)-1H-imidazole Drug Info IC50 = 151 nM [530679]
4-(4'-Fluoro-biphenyl-4-ylmethyl)pyridine Drug Info IC50 = 928 nM [531085]
3-Imidazol-1-ylmethyl-2-isopropyl-1H-indole Drug Info IC50 = 2000 nM [533418]
ABIRATERONE Drug Info IC50 = 1610 nM [530974]
3-(1-Chloro-7-methoxy-naphthalen-2-yl)-pyridine Drug Info IC50 = 2724 nM [527801]
3-(2-Chloro-1,1-dimethyl-2-phenyl-ethyl)-pyridine Drug Info IC50 = 1630 nM [533562]
3-(3-Benzyl-6-methoxynaphthalen-2-yl)pyridine Drug Info IC50 = 640 nM [529667]
1-(4-Cyanobenzyl)-5-(4-pyridyl)-1H-imidazole Drug Info IC50 = 307 nM [530679]
1-(4-Cyanobenzyl)-5-(4-methylphenyl)-1H-imidazole Drug Info IC50 = 130 nM [530679]
1-(3-Bromobenzyl)-1H-imidazole Drug Info IC50 = 143 nM [530679]
1-(4-Cyanobenzyl)-5-hydroxymethyl-1H-imidazole Drug Info IC50 = 285 nM [530679]
1-(4-Cyanobenzyl)-5-bromo-1H-imidazole Drug Info IC50 = 73 nM [530679]
3-[1-(4-Bromobenzyl)-1H-imidazol-5-yl]-1-propanol Drug Info IC50 = 18 nM [530679]
3-((1H-imidazol-1-yl)methyl)aniline Drug Info IC50 = 390 nM [530679]
5-(6-Methoxynaphthalen-2-yl)pyridin-3-ol Drug Info IC50 = 8925 nM [529624]
2-Methyl-1,2-di-pyridin-3-yl-propylchloride Drug Info IC50 = 7250 nM [533562]
2-Methyl-1,2-di-pyridin-3-yl-1-methoxypropane Drug Info IC50 = 7300 nM [533562]
6-Pyridin-3-yl-3,4-dihydroquinoline-2(1H)-thione Drug Info IC50 = 580 nM [529834]
6-(pyridin-3-yl)-2-naphthonitrile Drug Info IC50 = 691 nM [529624]
1-(4-Aminobenzyl)-1H-imidazole Drug Info IC50 = 236 nM [530679]
6-Pyridin-3-yl-naphthalen-2-ol Drug Info IC50 = 2671 nM [527801]
1-Naphthalen-2-yl-1H-imidazole Drug Info IC50 = 1317 nM [527801]
4'-(Pyridin-4-ylmethyl)biphenyl-3,4-diol Drug Info IC50 = 1400 nM [531085]
1-(4-Bromobenzyl)-1H-imidazole Drug Info IC50 = 211 nM [530679]
1-(4-Cyanobenzyl)-5-(2-fluorophenyl)-1H-imidazole Drug Info IC50 = 20 nM [530679]
6-Pyridin-3-yl-1,2,3,4-tetrahydronaphthalen-2-ol Drug Info IC50 = 4921 nM [529834]
1-(4-Cyanobenzyl)-5-phenyl-1H-imidazole Drug Info IC50 = 28 nM [530679]
1-Phenyl-2-pyridin-3-yl-propan-1-one Drug Info IC50 = 7720 nM [533562]
3-(1,1-Dimethyl-2-phenyl-ethyl)-pyridine Drug Info IC50 = 660 nM [533562]
6-(4-Methylpyridin-3-yl)-2-naphthonitrile Drug Info IC50 = 52 nM [529624]
4-(6-Methoxynaphthalen-2-yl)isoquinoline Drug Info IC50 = 67 nM [529624]
3-(6-Methoxynaphthalen-2-yl)-4-methylpyridine Drug Info IC50 = 114 nM [529624]
3-Imidazol-1-ylmethyl-1H-indole Drug Info IC50 = 10000 nM [533418]
3-[7-Methoxy-indan-(1E)-ylidenemethyl]-pyridine Drug Info IC50 = 955 nM [527456]
3-[5-Methoxy-indan-(1E)-ylidenemethyl]-pyridine Drug Info IC50 = 1448 nM [527456]
4-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyridine Drug Info IC50 = 1098 nM [527456]
3-[5-Chloro-indan-(1Z)-ylidenemethyl]-pyridine Drug Info IC50 = 270 nM [527456]
3-[5-Ethoxy-indan-(1Z)-ylidenemethyl]-pyridine Drug Info IC50 = 2697 nM [527456]
3-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyridine Drug Info IC50 = 311 nM [527456]
3-(1H-inden-2-yl)pyridine Drug Info IC50 = 2391 nM [528109]
3-[4-Chloro-indan-(1Z)-ylidenemethyl]-pyridine Drug Info IC50 = 657 nM [527456]
3-Indan-(1Z)-ylidenemethyl-pyridine Drug Info IC50 = 87 nM [527456]
4-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine Drug Info IC50 = 34 nM [527456]
3-(5-Bromo-6-methoxy-naphthalen-2-yl)-pyridine Drug Info IC50 = 4481 nM [527801]
3-(1-ethyl-3,4-dihydronaphthalen-2-yl)-pyridine Drug Info IC50 = 2117 nM [528109]
3-(4-methyl-3,4-dihydronaphthalen-2-yl)pyridine Drug Info IC50 = 1291 nM [528109]
3-[5-Bromo-indan-(1Z)-ylidenemethyl]-pyridine Drug Info IC50 = 320 nM [527456]
3-(3-methyl-3,4-dihydronaphthalen-2-yl)pyridine Drug Info IC50 = 503 nM [528109]
5-Indan-(1E)-ylidenemethyl-1H-imidazole Drug Info IC50 = 25.9 nM [527475]
5-Indan-(1Z)-ylidenemethyl-1H-imidazole Drug Info IC50 = 6.1 nM [527475]
3-(6-Methoxynaphthalen-2-yl)-5-phenylpyridine Drug Info IC50 = 151 nM [529624]
3-(5,6,7,8-Tetrahydronaphthalen-2-yl)pyridine Drug Info IC50 = 1977 nM [529834]
4-(2-Imidazol-1-yl-ethoxy)-benzamide Drug Info IC50 = 10000 nM [533496]
Metyrapone Drug Info Ki = 140 uM [553152]
3-(2,3-Dihydro-1,4-benzodioxin-6-yl)pyridine Drug Info IC50 = 13378 nM [529834]
3-(5-Chloro-6-methoxy-naphthalen-2-yl)-pyridine Drug Info IC50 = 2517 nM [527801]
4-Indan-(1Z)-ylidenemethyl-pyridine Drug Info IC50 = 931 nM [527456]
3-[5-Bromo-indan-(1E)-ylidenemethyl]-pyridine Drug Info IC50 = 1937 nM [527456]
3-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine Drug Info IC50 = 125 nM [527456]
3-[5-Chloro-indan-(1E)-ylidenemethyl]-pyridine Drug Info IC50 = 1472 nM [527456]
3-Indan-(1E)-ylidenemethyl-pyridine Drug Info IC50 = 888 nM [527456]
5-Pyridin-3-yl-2,3-dihydro-1H-inden-1-one Drug Info IC50 = 819 nM [529834]
1-(3-Methoxy-naphthalen-2-yl)-1H-imidazole Drug Info IC50 = 81 nM [527801]
3-(3,4-dihydronaphthalen-2-yl)pyridine Drug Info IC50 = 1729 nM [528109]
N-(4'-Isonicotinoylbiphenyl-3-yl)acetamide Drug Info IC50 = 307 nM [531085]
4'-(Pyridin-4-ylmethyl)biphenyl-3,4-diamine Drug Info IC50 = 902 nM [531085]
5-[4-(Pyridin-4-ylmethyl)phenyl]-1H-indole Drug Info IC50 = 469 nM [531085]
3-[4-Chloro-indan-(1E)-ylidenemethyl]-pyridine Drug Info IC50 = 304 nM [527456]
5-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyrimidine Drug Info IC50 = 27 nM [527456]
4-[(3'-Hydroxybiphenyl-4-yl)methyl]pyridine Drug Info IC50 = 342 nM [531085]
4-[5-Bromo-indan-(1E)-ylidenemethyl]-pyridine Drug Info IC50 = 2640 nM [527456]
4-[5-Bromo-indan-(1Z)-ylidenemethyl]-pyridine Drug Info IC50 = 484 nM [527456]
4-[5-Chloro-indan-(1Z)-ylidenemethyl]-pyridine Drug Info IC50 = 301 nM [527456]
3-[4-Fluoro-indan-(1E)-ylidenemethyl]-pyridine Drug Info IC50 = 774 nM [527456]
2-Methyl-1-phenyl-2-pyridin-3-yl-propan-1-one Drug Info IC50 = 3300 nM [533562]
3-(1,2-dihydroacenaphthylen-3-yl)pyridine Drug Info IC50 = 2452 nM [527819]
2-Methyl-1-phenyl-2-pyridin-3-yl-propan-1-ol Drug Info IC50 = 1530 nM [533562]
3-(naphthalen-2-yl)pyridine Drug Info IC50 = 5826 nM [529667]
1-(4-Cyanobenzyl)-5-(4-fluorophenyl)-1H-imidazole Drug Info IC50 = 27 nM [530679]
1-(4-Fluorobenzyl)-5-phenyl-1H-imidazole Drug Info IC50 = 16 nM [530679]
3-(1,2-dihydroacenaphthylen-5-yl)pyridine Drug Info IC50 = 2896 nM [527819]
2-Methyl-1,2-di-pyridin-3-yl-propan-1-one oxime Drug Info IC50 = 4780 nM [533562]
3-(6-methoxynaphthalen-2-yl)pyridine Drug Info IC50 = 1577 nM [529667]
3-[3-(4-Methoxybenzyl)naphthalen-2-yl]pyridine Drug Info IC50 = 2804 nM [529667]
1-Ethyl-3-imidazol-1-ylmethyl-1H-indole Drug Info IC50 = 10000 nM [533418]
3-(6-Bromo-naphthalen-2-yl)-pyridine Drug Info IC50 = 2939 nM [527801]
5-Naphthalen-2-yl-1H-imidazole Drug Info IC50 = 207 nM [527801]
4'-(Pyridin-4-ylmethyl)biphenyl-3-amine Drug Info IC50 = 287 nM [531085]
References
Ref 530679J Med Chem. 2010 Feb 25;53(4):1712-25.Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).
Ref 529624J Med Chem. 2008 Aug 28;51(16):5064-74. Epub 2008 Aug 1.Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization onpotency and selectivity.
Ref 529624J Med Chem. 2008 Aug 28;51(16):5064-74. Epub 2008 Aug 1.Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization onpotency and selectivity.
Ref 527475J Med Chem. 2005 Mar 24;48(6):1796-805.Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase.
Ref 531085J Med Chem. 2010 Aug 12;53(15):5749-58.Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.
Ref 531085J Med Chem. 2010 Aug 12;53(15):5749-58.Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.
Ref 531085J Med Chem. 2010 Aug 12;53(15):5749-58.Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.
Ref 531085J Med Chem. 2010 Aug 12;53(15):5749-58.Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.
Ref 531085J Med Chem. 2010 Aug 12;53(15):5749-58.Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.
Ref 527801J Med Chem. 2005 Oct 20;48(21):6632-42.Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis.
Ref 531085J Med Chem. 2010 Aug 12;53(15):5749-58.Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.
Ref 533562J Med Chem. 1984 Jan;27(1):15-9.Structure-activity relationship study of the inhibition of adrenal cortical 11 beta-hydroxylase by new metyrapone analogues.
Ref 527456J Med Chem. 2005 Mar 10;48(5):1563-75.Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase.
Ref 529624J Med Chem. 2008 Aug 28;51(16):5064-74. Epub 2008 Aug 1.Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization onpotency and selectivity.
Ref 529834J Med Chem. 2008 Dec 25;51(24):8077-87.In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.
Ref 529624J Med Chem. 2008 Aug 28;51(16):5064-74. Epub 2008 Aug 1.Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization onpotency and selectivity.
Ref 527456J Med Chem. 2005 Mar 10;48(5):1563-75.Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase.
Ref 529624J Med Chem. 2008 Aug 28;51(16):5064-74. Epub 2008 Aug 1.Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization onpotency and selectivity.
Ref 531085J Med Chem. 2010 Aug 12;53(15):5749-58.Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.
Ref 533562J Med Chem. 1984 Jan;27(1):15-9.Structure-activity relationship study of the inhibition of adrenal cortical 11 beta-hydroxylase by new metyrapone analogues.
Ref 527801J Med Chem. 2005 Oct 20;48(21):6632-42.Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis.
Ref 530679J Med Chem. 2010 Feb 25;53(4):1712-25.Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).
Ref 528109J Med Chem. 2006 Apr 6;49(7):2222-31.Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis.
Ref 528109J Med Chem. 2006 Apr 6;49(7):2222-31.Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis.
Ref 527801J Med Chem. 2005 Oct 20;48(21):6632-42.Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis.
Ref 528109J Med Chem. 2006 Apr 6;49(7):2222-31.Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis.
Ref 529834J Med Chem. 2008 Dec 25;51(24):8077-87.In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.
Ref 529624J Med Chem. 2008 Aug 28;51(16):5064-74. Epub 2008 Aug 1.Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization onpotency and selectivity.
Ref 533562J Med Chem. 1984 Jan;27(1):15-9.Structure-activity relationship study of the inhibition of adrenal cortical 11 beta-hydroxylase by new metyrapone analogues.
Ref 527475J Med Chem. 2005 Mar 24;48(6):1796-805.Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase.
Ref 530679J Med Chem. 2010 Feb 25;53(4):1712-25.Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).
Ref 530679J Med Chem. 2010 Feb 25;53(4):1712-25.Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).
Ref 530679J Med Chem. 2010 Feb 25;53(4):1712-25.Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).
Ref 530679J Med Chem. 2010 Feb 25;53(4):1712-25.Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).
Ref 530679J Med Chem. 2010 Feb 25;53(4):1712-25.Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).
Ref 530679J Med Chem. 2010 Feb 25;53(4):1712-25.Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).
Ref 530679J Med Chem. 2010 Feb 25;53(4):1712-25.Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).
Ref 530679J Med Chem. 2010 Feb 25;53(4):1712-25.Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).
Ref 528109J Med Chem. 2006 Apr 6;49(7):2222-31.Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis.
Ref 529667J Med Chem. 2008 Oct 9;51(19):6138-49. Epub 2008 Sep 3.Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach.
Ref 527801J Med Chem. 2005 Oct 20;48(21):6632-42.Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis.
Ref 528109J Med Chem. 2006 Apr 6;49(7):2222-31.Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis.
Ref 530679J Med Chem. 2010 Feb 25;53(4):1712-25.Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).
Ref 530679J Med Chem. 2010 Feb 25;53(4):1712-25.Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).
Ref 530679J Med Chem. 2010 Feb 25;53(4):1712-25.Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).
Ref 530679J Med Chem. 2010 Feb 25;53(4):1712-25.Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).
Ref 527801J Med Chem. 2005 Oct 20;48(21):6632-42.Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis.
Ref 530679J Med Chem. 2010 Feb 25;53(4):1712-25.Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).
Ref 530679J Med Chem. 2010 Feb 25;53(4):1712-25.Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).
Ref 530679J Med Chem. 2010 Feb 25;53(4):1712-25.Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).
Ref 527456J Med Chem. 2005 Mar 10;48(5):1563-75.Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase.
Ref 530679J Med Chem. 2010 Feb 25;53(4):1712-25.Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).
Ref 528109J Med Chem. 2006 Apr 6;49(7):2222-31.Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis.
Ref 527456J Med Chem. 2005 Mar 10;48(5):1563-75.Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase.
Ref 529834J Med Chem. 2008 Dec 25;51(24):8077-87.In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.
Ref 529834J Med Chem. 2008 Dec 25;51(24):8077-87.In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.
Ref 529834J Med Chem. 2008 Dec 25;51(24):8077-87.In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.
Ref 530679J Med Chem. 2010 Feb 25;53(4):1712-25.Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).
Ref 530679J Med Chem. 2010 Feb 25;53(4):1712-25.Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).
Ref 531085J Med Chem. 2010 Aug 12;53(15):5749-58.Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.
Ref 533418J Med Chem. 1986 Mar;29(3):342-6.Selective thromboxane synthetase inhibitors. 2. 3-(1H-imidazol-1-ylmethyl)-2-methyl-1H-indole-1-propanoic acid and analogues.
Ref 530974J Med Chem. 2010 Jul 8;53(13):5049-53.Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.
Ref 527801J Med Chem. 2005 Oct 20;48(21):6632-42.Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis.
Ref 533562J Med Chem. 1984 Jan;27(1):15-9.Structure-activity relationship study of the inhibition of adrenal cortical 11 beta-hydroxylase by new metyrapone analogues.
Ref 529667J Med Chem. 2008 Oct 9;51(19):6138-49. Epub 2008 Sep 3.Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach.
Ref 530679J Med Chem. 2010 Feb 25;53(4):1712-25.Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).
Ref 530679J Med Chem. 2010 Feb 25;53(4):1712-25.Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).
Ref 530679J Med Chem. 2010 Feb 25;53(4):1712-25.Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).
Ref 530679J Med Chem. 2010 Feb 25;53(4):1712-25.Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).
Ref 530679J Med Chem. 2010 Feb 25;53(4):1712-25.Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).
Ref 530679J Med Chem. 2010 Feb 25;53(4):1712-25.Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).
Ref 530679J Med Chem. 2010 Feb 25;53(4):1712-25.Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).
Ref 529624J Med Chem. 2008 Aug 28;51(16):5064-74. Epub 2008 Aug 1.Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization onpotency and selectivity.
Ref 533562J Med Chem. 1984 Jan;27(1):15-9.Structure-activity relationship study of the inhibition of adrenal cortical 11 beta-hydroxylase by new metyrapone analogues.
Ref 533562J Med Chem. 1984 Jan;27(1):15-9.Structure-activity relationship study of the inhibition of adrenal cortical 11 beta-hydroxylase by new metyrapone analogues.
Ref 529834J Med Chem. 2008 Dec 25;51(24):8077-87.In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.
Ref 529624J Med Chem. 2008 Aug 28;51(16):5064-74. Epub 2008 Aug 1.Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization onpotency and selectivity.
Ref 530679J Med Chem. 2010 Feb 25;53(4):1712-25.Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).
Ref 527801J Med Chem. 2005 Oct 20;48(21):6632-42.Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis.
Ref 527801J Med Chem. 2005 Oct 20;48(21):6632-42.Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis.
Ref 531085J Med Chem. 2010 Aug 12;53(15):5749-58.Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.
Ref 530679J Med Chem. 2010 Feb 25;53(4):1712-25.Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).
Ref 530679J Med Chem. 2010 Feb 25;53(4):1712-25.Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).
Ref 529834J Med Chem. 2008 Dec 25;51(24):8077-87.In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.
Ref 530679J Med Chem. 2010 Feb 25;53(4):1712-25.Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).
Ref 533562J Med Chem. 1984 Jan;27(1):15-9.Structure-activity relationship study of the inhibition of adrenal cortical 11 beta-hydroxylase by new metyrapone analogues.
Ref 533562J Med Chem. 1984 Jan;27(1):15-9.Structure-activity relationship study of the inhibition of adrenal cortical 11 beta-hydroxylase by new metyrapone analogues.
Ref 529624J Med Chem. 2008 Aug 28;51(16):5064-74. Epub 2008 Aug 1.Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization onpotency and selectivity.
Ref 529624J Med Chem. 2008 Aug 28;51(16):5064-74. Epub 2008 Aug 1.Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization onpotency and selectivity.
Ref 529624J Med Chem. 2008 Aug 28;51(16):5064-74. Epub 2008 Aug 1.Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization onpotency and selectivity.
Ref 533418J Med Chem. 1986 Mar;29(3):342-6.Selective thromboxane synthetase inhibitors. 2. 3-(1H-imidazol-1-ylmethyl)-2-methyl-1H-indole-1-propanoic acid and analogues.
Ref 527456J Med Chem. 2005 Mar 10;48(5):1563-75.Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase.
Ref 527456J Med Chem. 2005 Mar 10;48(5):1563-75.Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase.
Ref 527456J Med Chem. 2005 Mar 10;48(5):1563-75.Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase.
Ref 527456J Med Chem. 2005 Mar 10;48(5):1563-75.Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase.
Ref 527456J Med Chem. 2005 Mar 10;48(5):1563-75.Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase.
Ref 527456J Med Chem. 2005 Mar 10;48(5):1563-75.Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase.
Ref 528109J Med Chem. 2006 Apr 6;49(7):2222-31.Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis.
Ref 527456J Med Chem. 2005 Mar 10;48(5):1563-75.Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase.
Ref 527456J Med Chem. 2005 Mar 10;48(5):1563-75.Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase.
Ref 527456J Med Chem. 2005 Mar 10;48(5):1563-75.Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase.
Ref 527801J Med Chem. 2005 Oct 20;48(21):6632-42.Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis.
Ref 528109J Med Chem. 2006 Apr 6;49(7):2222-31.Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis.
Ref 528109J Med Chem. 2006 Apr 6;49(7):2222-31.Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis.
Ref 527456J Med Chem. 2005 Mar 10;48(5):1563-75.Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase.
Ref 528109J Med Chem. 2006 Apr 6;49(7):2222-31.Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis.
Ref 527475J Med Chem. 2005 Mar 24;48(6):1796-805.Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase.
Ref 527475J Med Chem. 2005 Mar 24;48(6):1796-805.Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase.
Ref 529624J Med Chem. 2008 Aug 28;51(16):5064-74. Epub 2008 Aug 1.Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization onpotency and selectivity.
Ref 529834J Med Chem. 2008 Dec 25;51(24):8077-87.In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.
Ref 533496J Med Chem. 1985 Oct;28(10):1427-32.Selective thromboxane synthetase inhibitors. 1. 1-[(Aryloxy)alkyl]-1H-imidazoles.
Ref 553152Mitochondrial cytochrome p450. A component of chick kidney 25-hydrocholecalciferol-1alpha-hydroxylase. J Biol Chem. 1974 May 25;249(10):3026-33.
Ref 529834J Med Chem. 2008 Dec 25;51(24):8077-87.In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.
Ref 527801J Med Chem. 2005 Oct 20;48(21):6632-42.Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis.
Ref 527456J Med Chem. 2005 Mar 10;48(5):1563-75.Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase.
Ref 527456J Med Chem. 2005 Mar 10;48(5):1563-75.Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase.
Ref 527456J Med Chem. 2005 Mar 10;48(5):1563-75.Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase.
Ref 527456J Med Chem. 2005 Mar 10;48(5):1563-75.Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase.
Ref 527456J Med Chem. 2005 Mar 10;48(5):1563-75.Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase.
Ref 529834J Med Chem. 2008 Dec 25;51(24):8077-87.In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.
Ref 527801J Med Chem. 2005 Oct 20;48(21):6632-42.Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis.
Ref 528109J Med Chem. 2006 Apr 6;49(7):2222-31.Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis.
Ref 531085J Med Chem. 2010 Aug 12;53(15):5749-58.Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.
Ref 531085J Med Chem. 2010 Aug 12;53(15):5749-58.Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.
Ref 531085J Med Chem. 2010 Aug 12;53(15):5749-58.Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.
Ref 527456J Med Chem. 2005 Mar 10;48(5):1563-75.Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase.
Ref 527456J Med Chem. 2005 Mar 10;48(5):1563-75.Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase.
Ref 531085J Med Chem. 2010 Aug 12;53(15):5749-58.Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.
Ref 527456J Med Chem. 2005 Mar 10;48(5):1563-75.Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase.
Ref 527456J Med Chem. 2005 Mar 10;48(5):1563-75.Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase.
Ref 527456J Med Chem. 2005 Mar 10;48(5):1563-75.Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase.
Ref 527456J Med Chem. 2005 Mar 10;48(5):1563-75.Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase.
Ref 533562J Med Chem. 1984 Jan;27(1):15-9.Structure-activity relationship study of the inhibition of adrenal cortical 11 beta-hydroxylase by new metyrapone analogues.
Ref 527819Bioorg Med Chem Lett. 2006 Jan 1;16(1):25-30. Epub 2005 Oct 21.Development and evaluation of a pharmacophore model for inhibitors of aldosterone synthase (CYP11B2).
Ref 533562J Med Chem. 1984 Jan;27(1):15-9.Structure-activity relationship study of the inhibition of adrenal cortical 11 beta-hydroxylase by new metyrapone analogues.
Ref 529667J Med Chem. 2008 Oct 9;51(19):6138-49. Epub 2008 Sep 3.Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach.
Ref 530679J Med Chem. 2010 Feb 25;53(4):1712-25.Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).
Ref 530679J Med Chem. 2010 Feb 25;53(4):1712-25.Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).
Ref 527819Bioorg Med Chem Lett. 2006 Jan 1;16(1):25-30. Epub 2005 Oct 21.Development and evaluation of a pharmacophore model for inhibitors of aldosterone synthase (CYP11B2).
Ref 533562J Med Chem. 1984 Jan;27(1):15-9.Structure-activity relationship study of the inhibition of adrenal cortical 11 beta-hydroxylase by new metyrapone analogues.
Ref 529667J Med Chem. 2008 Oct 9;51(19):6138-49. Epub 2008 Sep 3.Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach.
Ref 529667J Med Chem. 2008 Oct 9;51(19):6138-49. Epub 2008 Sep 3.Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach.
Ref 533418J Med Chem. 1986 Mar;29(3):342-6.Selective thromboxane synthetase inhibitors. 2. 3-(1H-imidazol-1-ylmethyl)-2-methyl-1H-indole-1-propanoic acid and analogues.
Ref 527801J Med Chem. 2005 Oct 20;48(21):6632-42.Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis.
Ref 527801J Med Chem. 2005 Oct 20;48(21):6632-42.Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis.
Ref 531085J Med Chem. 2010 Aug 12;53(15):5749-58.Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.